Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyEthchlorvynol
Identification
- Name
- Ethchlorvynol
- Accession Number
- DB00189 (APRD00958)
- Type
- Small Molecule
- Groups
- Approved, Illicit, Withdrawn
- Description
Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists. [Wikipedia]
- Structure
Structure for DB00189 (Ethchlorvynol)
- Synonyms
- 1-chloro-3-ethyl-1-penten-4-yn-3-ol
- 1-Chloro-3-ethyl-pent-1-en-4-yn-3-ol
- 3-(beta-chlorovinyl)-1-pentyn-3-ol
- 3-(β-chlorovinyl)-1-pentyn-3-ol
- ethyl β-chlorovinyl ethynyl carbinol
- β-chlorovinyl ethyl ethynyl carbinol
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Placidyl Cap 200mg Capsule 200 mg Oral Abbott 1956-12-31 2008-06-10 Canada 
Placidyl Cap 500mg Capsule 500 mg Oral Abbott 1952-12-31 2008-06-06 Canada Placidyl Cap 750mg Capsule 750 mg Oral Abbott 1971-12-31 2008-06-06 Canada - International/Other Brands
- Arvynol (Pfizer) / Nostel (Dainippon) / Placidyl (Abbott) / Roeridorm (Pfizer-Roerig) / Serenesil (Abbott)
- Categories
- UNII
- 6EIM3851UZ
- CAS number
- 113-18-8
- Weight
- Average: 144.599
Monoisotopic: 144.034192617 - Chemical Formula
- C7H9ClO
- InChI Key
- ZEHYJZXQEQOSON-AATRIKPKSA-N
- InChI
- InChI=1S/C7H9ClO/c1-3-7(9,4-2)5-6-8/h1,5-6,9H,4H2,2H3/b6-5+
- IUPAC Name
- 1-chloro-3-ethylpent-1-en-4-yn-3-ol
- SMILES
- [H]C(Cl)=CC(O)(CC)C#C
Pharmacology
- Indication
Used for short-term hypnotic therapy in the management of insomnia for periods of up to one week in duration; however, this medication generally has been replaced by other sedative-hypnotic agents.
- Structured Indications
- Not Available
- Pharmacodynamics
Ethchlorvynol is a sedative drug and schedule IV (USA) controlled substance. It produces cerebral depression, however the exact mechanism of action is not known.
- Mechanism of action
Although the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates. Barbiturates bind at a distinct binding sites associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Target Actions Organism AGABA-A receptor (anion channel) positive allosteric modulatorHuman - Absorption
Rapidly absorbed from gastrointestinal tract.
- Volume of distribution
- Not Available
- Protein binding
35-50%
- Metabolism
About 90% of a dose is metabolized in the liver. Some ethchlorvynol may also be metabolized in the kidneys. Ethchlorvynol and metabolites undergo extensive enterohepatic recirculation.
- Route of elimination
- Not Available
- Half life
Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.
- Clearance
- Not Available
- Toxicity
Symptoms of overdose include thrombocytopenia.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7-Nitroindazole The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with 7-Nitroindazole. Experimental Acepromazine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Aceprometazine. Approved Adipiplon The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Ethchlorvynol. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Allopregnanolone. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Ethchlorvynol. Approved, Illicit, Investigational Amisulpride The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amitriptyline. Approved Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Ethchlorvynol. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amoxapine. Approved Amperozide The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amperozide. Experimental Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethchlorvynol. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Asenapine is combined with Ethchlorvynol. Approved Azaperone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Azaperone. Vet Approved Azelastine Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Baclofen The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Baclofen. Approved Barbital The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Barbital. Illicit Benperidol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benperidol. Investigational Benzocaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benzocaine. Approved Benzyl alcohol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benzyl alcohol. Approved Brexpiprazole The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brexpiprazole. Approved Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol. Approved Bromazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Ethchlorvynol. Approved, Illicit Bromisoval The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bromisoval. Experimental Bromperidol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bromperidol. Investigational Brompheniramine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brompheniramine. Approved Brotizolam The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brotizolam. Approved, Withdrawn Bupivacaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bupivacaine. Approved, Investigational Buprenorphine Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Ethchlorvynol. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Ethchlorvynol. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butalbital. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butamben. Approved Butethal The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butethal. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Ethchlorvynol. Approved, Illicit, Vet Approved Canertinib The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Canertinib. Investigational Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethchlorvynol. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carbinoxamine. Approved Carfentanil The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carfentanil. Illicit, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carisoprodol. Approved Cetirizine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cetirizine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chloral hydrate. Approved, Illicit, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethchlorvynol. Approved, Illicit Chlormezanone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlormezanone. Approved, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chloroprocaine. Approved Chlorphenamine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorphenamine. Approved Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethchlorvynol. Approved, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorprothixene. Approved, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorzoxazone. Approved Cinchocaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cinchocaine. Approved, Vet Approved Citalopram The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Citalopram. Approved Clemastine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clemastine. Approved Clidinium The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clidinium. Approved Clobazam The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clobazam. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clomipramine. Approved, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clonazepam. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clonidine. Approved Clopenthixol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Ethchlorvynol. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clothiapine. Experimental Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Ethchlorvynol. Approved Cocaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cocaine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Ethchlorvynol. Approved, Illicit Cyclizine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyclizine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethchlorvynol. Approved Cyproheptadine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyproheptadine. Approved Dantrolene The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dantrolene. Approved Dapiprazole The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dapiprazole. Approved Dapoxetine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dapoxetine. Investigational Deramciclane The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Ethchlorvynol. Approved Desipramine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desipramine. Approved Desloratadine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desloratadine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desvenlafaxine. Approved Detomidine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Detomidine. Vet Approved Dexbrompheniramine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dexbrompheniramine. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dexmedetomidine. Approved, Vet Approved Dextromoramide The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dextropropoxyphene. Approved, Illicit, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dezocine. Approved Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Ethchlorvynol. Approved, Illicit, Vet Approved Diethyl ether The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Diethyl ether. Experimental Difenoxin The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Difenoxin. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethchlorvynol. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydromorphine. Experimental, Illicit Dimenhydrinate The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dimenhydrinate. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethchlorvynol. Approved Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethchlorvynol. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Doramectin. Vet Approved Doxepin The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Doxepin. Approved Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with DPDPE. Investigational Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol. Approved, Illicit Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Drotebanol. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dyclonine. Approved Ecgonine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ecopipam. Investigational Efavirenz The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Efavirenz. Approved, Investigational Eltanolone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Eltanolone. Investigational Enflurane The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Enflurane. Approved, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Entacapone. Approved, Investigational Escitalopram The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Escitalopram. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Ethchlorvynol. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethchlorvynol. Approved Ethanol Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethosuximide The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethosuximide. Approved Ethotoin The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethotoin. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethyl chloride. Experimental Ethyl loflazepate The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethylmorphine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etifoxine. Withdrawn Etizolam The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etomidate. Approved Etoperidone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etoperidone. Approved Etorphine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etorphine. Illicit, Vet Approved Ezogabine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ezogabine. Approved Felbamate The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Felbamate. Approved Fencamfamine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fencamfamine. Approved, Illicit, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Ethchlorvynol. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fexofenadine. Approved Flibanserin The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flibanserin. Approved Fluanisone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluanisone. Experimental Fludiazepam The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fludiazepam. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flunarizine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flunitrazepam. Approved, Illicit Fluoxetine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Ethchlorvynol. Approved, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethchlorvynol. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Ethchlorvynol. Approved, Illicit Fluspirilene The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluspirilene. Approved Fluticasone propionate The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluticasone propionate. Approved Fluvoxamine The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ethchlorvynol. Approved, Investigational Fosphenytoin The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fosphenytoin. Approved Fospropofol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fospropofol. Approved, Illicit Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Ethchlorvynol. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gabapentin Enacarbil. Approved Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ethchlorvynol. Approved, Illicit Gepirone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Glutethimide. Approved, Illicit Guanfacine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Guanfacine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Halazepam. Approved, Illicit, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Haloperidol is combined with Ethchlorvynol. Approved Halothane The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Halothane. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Heroin. Approved, Illicit Hexobarbital The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hexobarbital. Approved Hydrocodone Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethchlorvynol. Approved, Illicit Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol. Approved Iloperidone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Iloperidone. Approved Imipramine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Imipramine. Approved Indalpine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Indalpine. Investigational, Withdrawn Indiplon The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Indiplon. Investigational Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Ethchlorvynol. Approved, Vet Approved Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Ethchlorvynol. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketobemidone. Approved Lamotrigine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lamotrigine. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levetiracetam. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levobupivacaine. Approved Levocabastine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levocabastine. Approved Levocetirizine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levocetirizine. Approved Levodopa The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levodopa. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levomethadyl Acetate. Approved Levomilnacipran The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levomilnacipran. Approved Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Ethchlorvynol. Approved Lidocaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lidocaine. Approved, Vet Approved Lithium The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lithium. Approved Lofentanil The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lofentanil. Illicit Loprazolam The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Loratadine. Approved Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Ethchlorvynol. Approved Lormetazepam The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lormetazepam. Approved Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Ethchlorvynol. Approved Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Ethchlorvynol. Approved Magnesium Sulfate Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol. Approved, Vet Approved Maprotiline The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Maprotiline. Approved Mebicar The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Meclizine. Approved Medazepam The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Medetomidine. Vet Approved Melatonin The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Melperone. Approved Mepivacaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mepivacaine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Ethchlorvynol. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Meptazinol. Experimental Mesoridazine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mesoridazine. Approved Metaxalone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Metaxalone. Approved Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Ethchlorvynol. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methadyl Acetate. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methocarbamol. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Ethchlorvynol. Approved Methotrimeprazine Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved Methoxyflurane The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methoxyflurane. Approved, Vet Approved Methsuximide The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methsuximide. Approved Methylecgonine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methylecgonine. Experimental Methylphenobarbital The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methylphenobarbital. Approved Metyrosine Ethchlorvynol may increase the sedative activities of Metyrosine. Approved Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Ethchlorvynol. Approved, Illicit Milnacipran The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Milnacipran. Approved Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol. Approved, Investigational Mirtazapine Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Molindone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Ethchlorvynol. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethchlorvynol. Approved Nefazodone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nefazodone. Approved, Withdrawn Nitrazepam The risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethchlorvynol. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ethchlorvynol. Approved, Vet Approved Norflurane The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Norflurane. Investigational Normethadone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nortriptyline. Approved Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Ethchlorvynol. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Olopatadine. Approved Ondansetron The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ondansetron. Approved Opium The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Opium. Approved, Illicit Orphenadrine Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Osanetant. Investigational Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Ethchlorvynol. Approved Oxethazaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxethazaine. Investigational Oxprenolol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxybuprocaine. Approved Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Ethchlorvynol. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethchlorvynol. Approved, Investigational, Vet Approved Paliperidone The risk or severity of adverse effects can be increased when Paliperidone is combined with Ethchlorvynol. Approved Paraldehyde Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved Paroxetine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Paroxetine. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Ethchlorvynol. Approved, Vet Approved Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethchlorvynol. Approved, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol. Approved Perazine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perazine. Investigational Perospirone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Ethchlorvynol. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Ethchlorvynol. Approved Phenazocine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenazocine. Experimental Phenibut The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenibut. Experimental Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethchlorvynol. Approved Phenoperidine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenoxyethanol. Approved Phenytoin The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenytoin. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Pimozide is combined with Ethchlorvynol. Approved Pipamperone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pipamperone. Approved Pipotiazine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pipotiazine. Approved Piritramide The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Piritramide. Investigational Pizotifen The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pizotifen. Approved Pomalidomide The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pomalidomide. Approved Pramipexole Ethchlorvynol may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Prazepam. Approved, Illicit Pregabalin The risk or severity of adverse effects can be increased when Pregabalin is combined with Ethchlorvynol. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Prilocaine. Approved Primidone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Primidone. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Procaine. Approved, Investigational, Vet Approved Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethchlorvynol. Approved, Vet Approved Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Ethchlorvynol. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Promethazine. Approved Propanidid The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Proparacaine. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Ethchlorvynol. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Protriptyline. Approved Proxibarbal The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with PSD502. Investigational Quazepam The risk or severity of adverse effects can be increased when Quazepam is combined with Ethchlorvynol. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Ethchlorvynol. Approved Quinisocaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ramelteon. Approved, Investigational Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Ethchlorvynol. Approved Remoxipride The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Remoxipride. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Ethchlorvynol. Approved Risperidone The risk or severity of adverse effects can be increased when Risperidone is combined with Ethchlorvynol. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ritanserin. Investigational Romifidine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Romifidine. Vet Approved Ropinirole Ethchlorvynol may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ropivacaine. Approved Rotigotine Ethchlorvynol may increase the sedative activities of Rotigotine. Approved Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Ethchlorvynol. Approved Scopolamine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Scopolamine. Approved Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Ethchlorvynol. Approved, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sertindole. Approved, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethchlorvynol. Approved, Vet Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol. Approved Stiripentol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Stiripentol. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethchlorvynol. Approved, Investigational Sulpiride The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sulpiride. Approved Sultopride The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sultopride. Experimental Suvorexant Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved Tandospirone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol. Approved Tasimelteon The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tasimelteon. Approved Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Ethchlorvynol. Approved Tetrabenazine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrabenazine. Approved Tetracaine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrodotoxin. Investigational Thalidomide Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Thiamylal The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiamylal. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiopental. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Ethchlorvynol. Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Ethchlorvynol. Approved Tiagabine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tiagabine. Approved Tiapride The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tiapride. Approved, Investigational Tiletamine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tilidine. Experimental Tizanidine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tizanidine. Approved Tolcapone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tolcapone. Approved, Withdrawn Topiramate The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Topiramate. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Ethchlorvynol. Approved, Investigational Trans-2-Phenylcyclopropylamine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trans-2-Phenylcyclopropylamine. Experimental Tranylcypromine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tranylcypromine. Approved Trazodone The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trazodone. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Ethchlorvynol. Approved Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trichloroethylene. Experimental Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethchlorvynol. Approved Trifluperidol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triflupromazine. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trimipramine. Approved Triprolidine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triprolidine. Approved Valproic Acid The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Valproic Acid. Approved, Investigational Venlafaxine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Veralipride. Experimental Vigabatrin The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vigabatrin. Approved Vinyl ether The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vinyl ether. Experimental Vortioxetine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vortioxetine. Approved Xenon The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Xylazine. Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Ethchlorvynol. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ziconotide. Approved Zimelidine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zimelidine. Withdrawn Ziprasidone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethchlorvynol. Approved Zolazepam The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zolazepam. Vet Approved Zolpidem Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zonisamide. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Zopiclone is combined with Ethchlorvynol. Approved Zotepine The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zotepine. Approved Zuclopenthixol The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethchlorvynol. Approved, Investigational - Food Interactions
- Avoid alcohol
- Take with food to reduce irritation.
References
- Synthesis Reference
Bayley, A. and McLamore, W.M.; U.S. Patent 2,746,900; May 22,1956; assigned to Chas. Pfizer & Co., Inc.
- General References
- Not Available
- External Links
- KEGG Drug
- D00704
- KEGG Compound
- C07833
- PubChem Compound
- 5281077
- PubChem Substance
- 46505006
- ChemSpider
- 4444534
- ChEBI
- 4882
- ChEMBL
- CHEMBL591
- Therapeutic Targets Database
- DAP000163
- PharmGKB
- PA164746383
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Ethchlorvynol
- ATC Codes
- N05CM08 — Ethchlorvynol
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Banner pharmacaps inc
- Abbott laboratories pharmaceutical products div
- Packagers
- Not Available
- Dosage forms
Form Route Strength Capsule Oral 200 mg Capsule Oral 500 mg Capsule Oral 750 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
Property Value Source boiling point (°C) 28.5-30 Bayley, A. and McLamore, W.M.; U.S. Patent 2,746,900; May 22,1956; assigned to Chas. Pfizer & Co., Inc. logP 1.8 Not Available - Predicted Properties
Property Value Source Water Solubility 0.143 mg/mL ALOGPS logP 1.45 ALOGPS logP 1.62 ChemAxon logS -3 ALOGPS pKa (Strongest Acidic) 12.88 ChemAxon pKa (Strongest Basic) -3.7 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 1 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 20.23 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 38.64 m3·mol-1 ChemAxon Polarizability 14.77 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9965 Blood Brain Barrier + 0.9685 Caco-2 permeable + 0.646 P-glycoprotein substrate Non-substrate 0.743 P-glycoprotein inhibitor I Non-inhibitor 0.9023 P-glycoprotein inhibitor II Non-inhibitor 0.9672 Renal organic cation transporter Non-inhibitor 0.9589 CYP450 2C9 substrate Non-substrate 0.7267 CYP450 2D6 substrate Non-substrate 0.9 CYP450 3A4 substrate Non-substrate 0.6176 CYP450 1A2 substrate Non-inhibitor 0.5224 CYP450 2C9 inhibitor Non-inhibitor 0.6241 CYP450 2D6 inhibitor Non-inhibitor 0.9316 CYP450 2C19 inhibitor Inhibitor 0.5539 CYP450 3A4 inhibitor Non-inhibitor 0.7814 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7382 Ames test AMES toxic 0.867 Carcinogenicity Carcinogens 0.8102 Biodegradation Not ready biodegradable 0.9614 Rat acute toxicity 2.7881 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9406 hERG inhibition (predictor II) Non-inhibitor 0.9289
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as ynones. These are organic compounds containing the ynone functional group, an alpha,beta unsaturated ketone group with the general structure RC#C-C(=O)R' (R' not H).
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbonyl compounds
- Direct Parent
- Ynones
- Alternative Parents
- Tertiary alcohols / Vinyl chlorides / Chloroalkenes / Acetylides / Organochlorides / Hydrocarbon derivatives
- Substituents
- Ynone / Tertiary alcohol / Acetylide / Chloroalkene / Haloalkene / Vinyl halide / Vinyl chloride / Hydrocarbon derivative / Organochloride / Organohalogen compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- terminal acetylenic compound, tertiary alcohol, organochlorine compound, enyne (CHEBI:4882)
Targets
- Kind
- Protein group
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Positive allosteric modulator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Components:
References
- Smeyatsky N, Baldwin D, Botros W, Gura R, Kurian T, Lambert MT, Patel AG, Steinert J, Priest RG: The treatment of sleep disorders. S Afr Med J. 1992 May 2;Suppl:1-8. [PubMed:1585214]
- ChEMBL Compound Report Card [Link]
Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:32